Novel method to assess arterial insufficiency in rodent hind limb.

Matthew A Ziegler, Matthew R DiStasi, Steven J Miller, Michael C Dalsing, Joseph L Unthank
Author Information
  1. Matthew A Ziegler: Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana.
  2. Matthew R DiStasi: Departments of Pediatrics, and Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana.
  3. Steven J Miller: Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana; Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana.
  4. Michael C Dalsing: Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana.
  5. Joseph L Unthank: Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana; Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address: junthank@iupui.edu.

Abstract

BACKGROUND: Lack of techniques to assess maximal blood flow capacity thwarts the use of rodent models of arterial insufficiency to evaluate therapies for intermittent claudication. We evaluated femoral vein outflow (VO) in combination with stimulated muscle contraction as a potential method to assess functional hind limb arterial reserve and therapeutic efficacy in a rodent model of subcritical limb ischemia.
MATERIALS AND METHODS: VO was measured with perivascular flow probes at rest and during stimulated calf muscle contraction in young, healthy rats (Wistar Kyoto, WKY; lean Zucker rats, LZR) and rats with cardiovascular risk factors (spontaneously hypertensive [SHR]; obese Zucker rats [OZR]) with acute and/or chronic femoral arterial occlusion. Therapeutic efficacy was assessed by administration of Ramipril or Losartan to SHR after femoral artery excision.
RESULTS: VO measurement in WKY demonstrated the utility of this method to assess hind limb perfusion at rest and during calf muscle contraction. Although application to diseased models (OZR and SHR) demonstrated normal resting perfusion compared with contralateral limbs, a significant reduction in reserve capacity was uncovered with muscle stimulation. Administration of Ramipril and Losartan demonstrated significant improvement in functional arterial reserve.
CONCLUSIONS: The results demonstrate that this novel method to assess distal limb perfusion in small rodents with subcritical limb ischemia is sufficient to unmask perfusion deficits not apparent at rest, detect impaired compensation in diseased animal models with risk factors, and assess therapeutic efficacy. The approach provides a significant advance in methods to investigate potential mechanisms and novel therapies for subcritical limb ischemia in preclinical rodent models.

Keywords

References

  1. Proc Nutr Soc. 1999 Nov;58(4):887-98 [PMID: 10817156]
  2. Ann Thorac Surg. 2000 Jul;70(1):212-7 [PMID: 10921710]
  3. Arch Intern Med. 2000 Oct 23;160(19):2934-8 [PMID: 11041900]
  4. J Vasc Surg. 2001 Feb;33(2):251-7; discussion 257-8 [PMID: 11174775]
  5. J Surg Res. 2001 Jun 1;98(1):21-6 [PMID: 11368533]
  6. Hypertension. 2001 Jul;38(1):136-41 [PMID: 11463774]
  7. JAMA. 2001 Sep 19;286(11):1317-24 [PMID: 11560536]
  8. Circulation. 2001 Sep 25;104(13):1571-4 [PMID: 11571254]
  9. Am J Physiol Heart Circ Physiol. 2002 Jan;282(1):H301-10 [PMID: 11748075]
  10. Br J Pharmacol. 2002 Jan;135(1):87-92 [PMID: 11786483]
  11. Circulation. 2002 Apr 9;105(14):1639-41 [PMID: 11940540]
  12. Am J Hypertens. 2002 May;15(5):410-5 [PMID: 12022243]
  13. Microcirculation. 2002 Oct;9(5):343-51 [PMID: 12375172]
  14. Cardiovasc Res. 2002 Nov;56(2):293-302 [PMID: 12393100]
  15. J Nucl Med. 2003 Jun;44(6):915-9 [PMID: 12791819]
  16. Am J Physiol Heart Circ Physiol. 2003 Sep;285(3):H1190-7 [PMID: 12763749]
  17. Eur Surg Res. 2003 Sep-Oct;35(5):430-8 [PMID: 12928601]
  18. J Appl Physiol (1985). 2004 Aug;97(2):773-80 [PMID: 15107408]
  19. J Clin Invest. 1966 Jun;45(6):923-31 [PMID: 5913300]
  20. Acta Physiol Scand. 1968 Jul;73(3):257-63 [PMID: 5709583]
  21. Am J Physiol. 1980 Jan;238(1):H31-42 [PMID: 7356032]
  22. Circulation. 1985 Mar;71(3):510-5 [PMID: 3156006]
  23. Am J Physiol. 1987 Mar;252(3 Pt 2):H485-93 [PMID: 3493707]
  24. N Engl J Med. 1992 Feb 6;326(6):381-6 [PMID: 1729621]
  25. J Vasc Res. 1992 Sep-Oct;29(5):359-66 [PMID: 1330017]
  26. J Appl Physiol (1985). 1993 Jul;75(1):452-7 [PMID: 8397181]
  27. Clin Physiol. 1993 Sep;13(5):547-57 [PMID: 8222539]
  28. Hypertension. 1993 Nov;22(5):780-8 [PMID: 8225538]
  29. Am J Physiol. 1995 Jan;268(1 Pt 2):F175-8 [PMID: 7840243]
  30. Am J Physiol. 1995 Mar;268(3 Pt 2):H1368-72 [PMID: 7900889]
  31. J Appl Physiol (1985). 1995 Jan;78(1):93-100 [PMID: 7713849]
  32. J Cardiovasc Pharmacol. 1996 Jan;27(1):91-8 [PMID: 8656665]
  33. J Hypertens. 1997 Dec;15(12 Pt 1):1455-62 [PMID: 9431852]
  34. Eur Heart J. 1997 Dec;18(12):1931-6 [PMID: 9447321]
  35. Am J Hypertens. 2005 Sep;18(9 Pt 2):134S-141S [PMID: 16125050]
  36. Circ Res. 2005 Nov 25;97(11):1182-9 [PMID: 16239589]
  37. JAMA. 2006 Feb 1;295(5):547-53 [PMID: 16449620]
  38. Am J Physiol Heart Circ Physiol. 2006 Apr;290(4):H1362-9 [PMID: 16227342]
  39. Ann Intern Med. 2006 May 2;144(9):660-4 [PMID: 16670135]
  40. Circulation. 2006 Aug 15;114(7):688-99 [PMID: 16908785]
  41. Blood. 2006 Oct 1;108(7):2438-45 [PMID: 16735597]
  42. Am J Prev Med. 2007 Apr;32(4):328-33 [PMID: 17383564]
  43. Am J Physiol Heart Circ Physiol. 2007 Apr;292(4):H1891-7 [PMID: 17189353]
  44. Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2523-31 [PMID: 17277018]
  45. Diabetes. 2007 Dec;56(12):2872-7 [PMID: 17804761]
  46. Hypertension. 2008 Jun;51(6):1537-44 [PMID: 18426993]
  47. Diabetes. 2008 Oct;57(10):2577-87 [PMID: 18633100]
  48. Am J Physiol Heart Circ Physiol. 2009 Mar;296(3):H877-86 [PMID: 19151256]
  49. J Am Coll Cardiol. 2009 Mar 24;53(12):1063-4 [PMID: 19298920]
  50. J Cardiovasc Pharmacol. 2009 Jun;53(6):446-51 [PMID: 19433986]
  51. J Atheroscler Thromb. 2009 Aug;16(4):319-26 [PMID: 19672036]
  52. Microcirculation. 2010 Jan;17(1):3-20 [PMID: 20141596]
  53. J Cardiovasc Pharmacol. 2010 Feb;55(2):153-60 [PMID: 20173509]
  54. J Vasc Surg. 2011 May;53(5):1350-8 [PMID: 21276693]
  55. JAMA. 2013 Feb 6;309(5):453-60 [PMID: 23385271]
  56. JAMA. 2013 Feb 6;309(5):487-8 [PMID: 23385276]
  57. Atherosclerosis. 2013 Mar;227(1):1-8 [PMID: 23177969]
  58. Lancet. 2013 Oct 19;382(9901):1329-40 [PMID: 23915883]
  59. Lancet. 2013 Oct 19;382(9901):1312-4 [PMID: 23915884]
  60. Cardiovasc Diabetol. 2015;14:51 [PMID: 25964060]
  61. Am J Physiol. 1996 Dec;271(6 Pt 2):H2701-9 [PMID: 8997333]

Grants

  1. R01 HL042898/NHLBI NIH HHS
  2. T32 DK007519/NIDDK NIH HHS
  3. HL-42898/NHLBI NIH HHS
  4. T32DK007519/NIDDK NIH HHS

MeSH Term

Animals
Feasibility Studies
Femoral Artery
Femoral Vein
Hindlimb
Hyperemia
Ligation
Losartan
Male
Muscle Contraction
Peripheral Arterial Disease
Ramipril
Rats, Inbred WKY
Ultrasonography

Chemicals

Losartan
Ramipril

Word Cloud

Created with Highcharts 10.0.0limbassessmodelsarterialrodentmusclemethodreserveratsperfusionflowcapacityinsufficiencyfemoralVOcontractionhindefficacysubcriticalischemiarestdemonstratedsignificantArterialtherapiesstimulatedpotentialfunctionaltherapeuticcalfWKYZuckerriskfactorsocclusionRamiprilLosartanSHRdiseasednovelBACKGROUND:LacktechniquesmaximalbloodthwartsuseevaluateintermittentclaudicationevaluatedveinoutflowcombinationmodelMATERIALSANDMETHODS:measuredperivascularprobesyounghealthyWistarKyotoleanLZRcardiovascularspontaneouslyhypertensive[SHR]obese[OZR]acuteand/orchronicTherapeuticassessedadministrationarteryexcisionRESULTS:measurementutilityAlthoughapplicationOZRnormalrestingcomparedcontralaterallimbsreductionuncoveredstimulationAdministrationimprovementCONCLUSIONS:resultsdemonstratedistalsmallrodentssufficientunmaskdeficitsapparentdetectimpairedcompensationanimalapproachprovidesadvancemethodsinvestigatemechanismspreclinicalNovelPreclinicalVenous

Similar Articles

Cited By